Heredity

U.S. adults are still behind on routine cancer screenings—but reasons why vary by race

Retrieved on: 
Tuesday, April 2, 2024
Lung cancer, Health, Millennials, Child care, Confusion, Prostate cancer, Survival, Skin cancer, Disease, Colorectal cancer, Nervous, Risk, Cervical cancer, Heredity, Education, Patient, Cancer, Testicular cancer, Oral cancer, Generation Z, Breast cancer, Gen, Fear

The survey revealed that nearly seven in 10 U.S. adults are behind on at least one routine cancer screening.1

Key Points: 
  • The survey revealed that nearly seven in 10 U.S. adults are behind on at least one routine cancer screening.1
    The second annual survey, released during Cancer Prevention and Early Detection Month in April, indicates more U.S. adults are behind on routine cancer screenings compared to last year.
  • It is crucial to advocate for your health and talk to your health care provider about the routine cancer screenings you need.
  • “We are reaffirming our commitment to empowering people to stay ahead of cancer through prevention and early detection until all populations can achieve better outcomes—without any barriers to the process.”
    1The cancer screenings studied in this survey were for breast cancer, cervical cancer, colorectal cancer, lung cancer, oral cancer, prostate cancer, skin cancer and testicular cancer.
  • 2In this survey, Gen Z is defined as adults ages 21-27 and Millennials are defined as adults ages 28-43.

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neuroscience, Juno Therapeutics, Genentech, Cornell University, Heredity, Patient, Carmustine, Acquisition, Allergy, Senior, Research and development, Therapy, Drug development, Rituximab, Management

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.
  • Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
  • “It is a pleasure to welcome Sunil to our Board of Directors,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
  • “STAR-0215 has the potential to significantly improve the lives of patients and I look forward to contributing to its progress at this exciting time.”
    Dr. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences, MyoKardia, and Vitrisa Therapeutics.

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Retrieved on: 
Monday, March 18, 2024
Angioedema, Conference, EOP, Attack, Quality of life (healthcare), Network, Safety, HAE, Hereditary angioedema, Patient, Adolescence, Heredity, Country, National Congress, Physician, Medicine, Pharmaceutical industry

“We are committed to the continued advancement of our clinical development program of deucrictibant to fulfill unmet needs of current HAE treatment,” said Berndt Modig, Chief Executive Officer of Pharvaris.

Key Points: 
  • “We are committed to the continued advancement of our clinical development program of deucrictibant to fulfill unmet needs of current HAE treatment,” said Berndt Modig, Chief Executive Officer of Pharvaris.
  • The RAPIDe-3 study is designed to assess the effectiveness of deucrictibant in addressing that unmet need.
  • RAPIDe-3 is a randomized, double-blind, placebo-controlled, crossover study, which is designed to enroll approximately 120 adolescent and adult participants globally.
  • The data illustrates that HRQoL is negatively impacted, including functional and psychological impairment, in people with HAE.

Pathway to Cures Announces First Entrepreneur in Residence

Retrieved on: 
Monday, March 11, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Health, Philanthropy, Fund Raising, Foundation, Other Health, Disease, Coagulopathy, Sickle cell disease, Heredity, Spark Therapeutics, Rush University Medical Center, Entrepreneur in residence, Knowledge, Mortality, Baxalta, EIR, Doctor of Philosophy, MD, MBA, Therapy, Anemia, Blood

Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.

Key Points: 
  • Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.
  • Dr. Valentino most recently served as President and CEO of the National Bleeding Disorders Foundation (NBDF) and was instrumental in bringing Pathway to Cures into reality.
  • Pathway to Cures is the venture philanthropy fund of the NBDF focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “My role as Entrepreneur in Residence for Pathway to Cures will be to provide guidance into the consideration and support of new opportunities for catalyzing transformative therapies and cures.

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Retrieved on: 
Wednesday, March 6, 2024
Bradykinin receptor B2, Hereditary angioedema, Real, Safety, Heredity, Treatment, Conference, HAE, Network, Abstract, National Congress, Pharmaceutical industry

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) , to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas , to be held from March 15-17, 2024, in Panama City, Panama.

Key Points: 
  • ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) , to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas , to be held from March 15-17, 2024, in Panama City, Panama.
  • Details of the presentations are as follows:
    Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
    Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
    Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.
  • Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
    Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
    Title: Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    Title: Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
    The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations .

NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence

Retrieved on: 
Monday, March 4, 2024
Classification, Neoplasm, MD, System, Heredity, Bladder cancer, Lung, Principle, Conference, Breast, Lung cancer, Kidney cancer, NCCN, Pathology, Patient, Virtual, National Comprehensive Cancer Network, Medicine, Poster, Research, Medical imaging

PLYMOUTH MEETING, Pa., March 4, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for any area of medicine and are used by cancer care providers worldwide to stay up to date on innovations. Recently, the alliance of leading cancer centers published updated versions for several high-incidence cancer types, including breast, colorectal, lung, and pancreatic.

Key Points: 
  • Latest recommendations and underlying evidence will be explained at NCCN 2024 Annual Conference April 5-7.
  • PLYMOUTH MEETING, Pa., March 4, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
  • Recently, the alliance of leading cancer centers published updated versions for several high-incidence cancer types, including breast, colorectal, lung, and pancreatic.
  • Some recent updates to the NCCN Guidelines recommendations include:
    Updates to treatment of HR-positive, early-stage breast cancer, including a new page outlining the general principles for adjuvant endocrine therapy.

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
Wednesday, January 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

Gitanyow Nation Launches Defensive Stance Against Potential Transfer of Forestry License 16882

Retrieved on: 
Thursday, December 14, 2023
Marketing, Terrace Mill, Government, Bankruptcy, Kitwanga, Gitanyow, GHC, Heredity, Property management

This forestry license, deeply intertwined with Gitanyow’s traditional lands, presents an unmistakable and high potential for substantial adverse impacts on Gitanyow’s rights.

Key Points: 
  • This forestry license, deeply intertwined with Gitanyow’s traditional lands, presents an unmistakable and high potential for substantial adverse impacts on Gitanyow’s rights.
  • Despite a Cooperative Harvest Agreement previously in place with Gitanyow, SS's recent bankruptcy has put its assets, including FLA16882, in receivership.
  • The Simigigyet’m Gitanyow (Gitanyow Hereditary Chiefs) are an innovative, traditional Indigenous government mandated to protect Gitanyow Nation’s lands, resources, and laws.
  • Gitanyow Nation is part of the larger Gitksan Nation, encompassing 6,200 square kilometres in the Nass and Skeena Watersheds (Kitwanga and Kispiox Rivers).

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

Retrieved on: 
Friday, December 22, 2023
Research, FDA, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Quality of life, Tissue, Heart, Heredity, Serum, Polyneuropathy, Death, Inotersen, Ageing, TTR, JAMA, Vitamin A, Diagnosis, Metabolism, Amyloidosis, Pancreas, Disease, Safety, Journal, Heart failure, Disability studies, Sympathetic nervous system, Vitamin A deficiency, Food, Biopharmaceutical, AstraZeneca, Caregiver, ATTR, Patient, Medicine, LICA, Ionis, American Medical Association, Growth, Central nervous system, Pharmaceutical industry

It is also a pivotal moment for Ionis as WAINUA will be the first in a steady cadence of potential commercial launches for the company.

Key Points: 
  • It is also a pivotal moment for Ionis as WAINUA will be the first in a steady cadence of potential commercial launches for the company.
  • Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels.
  • Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.
  • Please see link to US Full Prescribing Information for WAINUA.

The 5th World Media Summit (Yunnan, China) and the 2nd Yunnan International Communication Forum kicks off

Retrieved on: 
Tuesday, December 12, 2023
Destinations, Media, Travel, Vacation, Communications, Arts, Museums, Tourist Attractions, Entertainment, Belt, Multimedia, Ecosystem, Han Chinese, Heredity, Plant, City, Belt and Road Initiative, Kingdom of Plants 3D, System, Biodiversity, Tea, Animal

More than 300 representatives of around 80 institutions, including media outlets, international organizations and think tanks, from nearly 30 countries and regions, gathered in Yunnan for the fifth World Media Summit and the second Yunnan International Communication Forum, which kicked off on December 5 in Kunming, the capital city of province Yunnan in southwest China.

Key Points: 
  • More than 300 representatives of around 80 institutions, including media outlets, international organizations and think tanks, from nearly 30 countries and regions, gathered in Yunnan for the fifth World Media Summit and the second Yunnan International Communication Forum, which kicked off on December 5 in Kunming, the capital city of province Yunnan in southwest China.
  • View the full release here: https://www.businesswire.com/news/home/20231211302806/en/
    The 5th World Media Summit (Yunnan Branch) and the 2nd Yunnan International Communication Forum kicks off in Kunming on Dec. 5 (Photo: Business Wire)
    While the Kunming Initiative has been adopted at the opening of the summit on 5th Dec., a theme activity named “There is a lifestyle called Yunnan” has been launched, and the international communication hot words list has been released by the Chinese media Xinhuanet.
  • Yunnan is the most ethnically diverse province in China, with 25 hereditary ethnic minorities in addition to the Han Chinese.
  • Now, Yunnan is creating an ecologically green, colorful, harmonious, and happy, open and inclusive “There is a lifestyle called Yunnan."